J INTERN MED: The relationship between apolipoprotein A-IV concentration and clinical outcome in patients with chronic kidney disease

Chronic kidney disease (CKD) is a chronic pro-inflammatory state, with higher heart vascular risks
.

Apolipoprotein A-IV (apoA-IV) has anti-atherosclerosis, anti-oxidant, anti-inflammatory and anti- thrombotic properties, and its level is significantly increased during the course of CKD

Vascular Thrombosis

Recently, an authoritative journal in the field of internal medicine published a research article in the Journal of Internal Medicine.
Researchers aimed to investigate the association between apoA-IV levels and all-cause mortality and cardiovascular outcomes in the German Chronic Kidney Disease (GCKD) study
.

This prospective cohort study included 5141 white patients with apoA-IV measurements and CKD
.

In the presence of significant proteinuria, the eGFR of most patients is 30-60mL/min/1.

The average concentration of apoA-IV in the entire cohort was 28.
9±9.
8 mg/dL
.

Although the prevalence of diabetes , proteinuria, and low eGFR is the highest, patients with apoA-IV levels in the top quartile have the lowest high-sensitivity C-reactive protein levels

Diabetic cardiovascular events

It can be seen that the data supports an association between increased apoA-IV concentration and reduced inflammation in patients with moderate CKD
.

In a large chronic kidney disease patient, ApoA-IV levels appear to be an independent risk marker for reducing all-cause mortality, cardiovascular events, and heart failure

This data supports an association between increased apoA-IV concentration and reduced inflammation in patients with moderate CKD

Original source:

Johannes P.

Apolipoprotein A-IV concentrations and clinical outcomes in a large chronic kidney disease cohort: results from the GCKD study in this message